Zacks: Analysts Set $6.50 Target Price for Edap Tms SA (NASDAQ:EDAP)

Shares of Edap Tms SA (NASDAQ:EDAP) have earned a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the company, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy recommendation.

Analysts have set a 12-month consensus target price of $6.50 for the company and are forecasting that the company will post $0.01 earnings per share for the current quarter, according to Zacks. Zacks has also assigned Edap Tms an industry rank of 97 out of 256 based on the ratings given to related companies.

Several analysts have recently issued reports on the company. Zacks Investment Research raised Edap Tms from a “hold” rating to a “strong-buy” rating and set a $5.50 price objective on the stock in a report on Tuesday, April 9th. ValuEngine raised Edap Tms from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. HC Wainwright set a $7.00 price objective on Edap Tms and gave the stock a “buy” rating in a report on Tuesday. Finally, TheStreet raised Edap Tms from a “c” rating to a “b-” rating in a report on Wednesday, May 8th.

Shares of EDAP traded up $0.02 during mid-day trading on Thursday, hitting $2.72. 4,182 shares of the stock were exchanged, compared to its average volume of 163,470. The stock has a market capitalization of $80.03 million, a price-to-earnings ratio of 134.00 and a beta of 2.23. Edap Tms has a 52-week low of $1.35 and a 52-week high of $5.42. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.40 and a quick ratio of 1.97.

Edap Tms (NASDAQ:EDAP) last issued its quarterly earnings data on Wednesday, May 15th. The medical equipment provider reported $0.01 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.01. The business had revenue of $11.50 million for the quarter, compared to analysts’ expectations of $13.25 million. Edap Tms had a negative return on equity of 1.13% and a negative net margin of 0.36%. On average, sell-side analysts expect that Edap Tms will post 0.08 earnings per share for the current year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Commonwealth Equity Services LLC grew its position in Edap Tms by 27.0% in the 1st quarter. Commonwealth Equity Services LLC now owns 23,500 shares of the medical equipment provider’s stock valued at $70,000 after acquiring an additional 5,000 shares during the last quarter. Hilton Capital Management LLC bought a new position in Edap Tms in the 1st quarter valued at $75,000. Finally, Fosun International Ltd grew its position in Edap Tms by 45.9% in the 1st quarter. Fosun International Ltd now owns 363,485 shares of the medical equipment provider’s stock valued at $1,072,000 after acquiring an additional 114,342 shares during the last quarter. 10.31% of the stock is currently owned by hedge funds and other institutional investors.

Edap Tms Company Profile

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally-invasive medical devices for the treatment of urological diseases worldwide. The company operates in two divisions: High Intensity Focused Ultrasound (HIFU), and Urology Devices and Services (UDS).

See Also: Dividend Achievers

Get a free copy of the Zacks research report on Edap Tms (EDAP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Edap Tms Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edap Tms and related companies with MarketBeat.com's FREE daily email newsletter.